[go: up one dir, main page]

BRPI0814256A8 - Inibidores de tetrahidropiranocromeno gama secretase - Google Patents

Inibidores de tetrahidropiranocromeno gama secretase

Info

Publication number
BRPI0814256A8
BRPI0814256A8 BRPI0814256A BRPI0814256A BRPI0814256A8 BR PI0814256 A8 BRPI0814256 A8 BR PI0814256A8 BR PI0814256 A BRPI0814256 A BR PI0814256A BR PI0814256 A BRPI0814256 A BR PI0814256A BR PI0814256 A8 BRPI0814256 A8 BR PI0814256A8
Authority
BR
Brazil
Prior art keywords
tertiary amine
basic tertiary
secretase inhibitors
heteroaryl
halide
Prior art date
Application number
BRPI0814256A
Other languages
English (en)
Inventor
Wu Wen-Lian
A Bara Thomas
A Burnett Duane
W Clader John
S Domalski Martin
Jin Yan
B Josien Hubert
Li Hongmei
Liang Xian
A Pissarnitski Dmitri
K Sasikumar Thavalakulamgara
K Wong Jesse
Xu Ruo
Zhao Zhiqiang
Mcnamara Paul
Original Assignee
Schering Corp
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Merck Sharp & Dohme filed Critical Schering Corp
Publication of BRPI0814256A2 publication Critical patent/BRPI0814256A2/pt
Publication of BRPI0814256A8 publication Critical patent/BRPI0814256A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

INIBIDORES DE TETRA-HIDROPIRANOCROMENOGAMA SECRETASE. A presente invenção refere-se a novos inibidores de gama secretase da fórmula: (I) Também revelados são métodos de inibição de gama-secretase, métodos de tratamento de doenças neurodegenerativas, e métodos de tratamento de doença de Alzheimer. Também revelados são processos para preparação de alquenos em uma etapa de reação usando-se uma mistura de um aldeído (ou cetona) e uma alquila substituída com dois grupos de retirada de elétron, e reação da mistura com: (a) a haleto desulfonila (por exemplo, a cloreto de sulfonila) e uma amina terciária básica, ou, (b) a anidreto de sulfonil e a amina básica, ou (c) um aril-C(O)-haleto e uma amina terciária básica, ou (d) um aril-C(O0)-O-C(O)-arila e uma amina terciária básica, ou (e) um heteroaril-C(O)-haleto e uma amina terciária básica, ou (f) um heteroaril-C(0)-O-C(O)-heteroarila e uma amina terciária básica.
BRPI0814256A 2007-07-05 2008-07-01 Inibidores de tetrahidropiranocromeno gama secretase BRPI0814256A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94803307P 2007-07-05 2007-07-05
PCT/US2008/008192 WO2009008980A2 (en) 2007-07-05 2008-07-01 Tetrahydropyranochromene gamma secretase inhibitors

Publications (2)

Publication Number Publication Date
BRPI0814256A2 BRPI0814256A2 (pt) 2015-02-03
BRPI0814256A8 true BRPI0814256A8 (pt) 2016-02-10

Family

ID=39830164

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814256A BRPI0814256A8 (pt) 2007-07-05 2008-07-01 Inibidores de tetrahidropiranocromeno gama secretase

Country Status (16)

Country Link
US (1) US8664411B2 (pt)
EP (1) EP2435416B1 (pt)
JP (1) JP5240871B2 (pt)
KR (1) KR20100044197A (pt)
CN (1) CN101754960A (pt)
AR (1) AR067445A1 (pt)
AU (1) AU2008275735B2 (pt)
BR (1) BRPI0814256A8 (pt)
CA (1) CA2691542A1 (pt)
CL (1) CL2008001960A1 (pt)
CO (1) CO6270309A2 (pt)
EC (1) ECSP109845A (pt)
PE (1) PE20090435A1 (pt)
RU (1) RU2483061C2 (pt)
TW (1) TW200908959A (pt)
WO (1) WO2009008980A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059075A1 (es) 2006-01-20 2008-03-12 Schering Corp Bencesulfonil - cromano , tiocromano tetrahidronaftaleno e inhibidores de gamma secretasa relacionados
WO2009011851A1 (en) 2007-07-17 2009-01-22 Schering Corporation Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
US8933116B2 (en) 2011-04-04 2015-01-13 Merck Sharp & Dohme Corp. Gamma secretase inhibitors
US9226927B2 (en) * 2011-09-09 2016-01-05 Merck Sharp & Dohme Corp. Gamma secretase inhibitors
WO2014085211A2 (en) * 2012-11-29 2014-06-05 Merck Sharp & Dohme Corp. Spirocyclic sulfones as gamma secretase inhibitors
KR102209418B1 (ko) * 2012-12-20 2021-01-29 얀센 파마슈티카 엔.브이. 감마 세크레타제 조절 인자로서의 신규 삼환 3,4-디하이드로-2H-피리도[1,2-α]피라진-1,6-디온 유도체
CA2891755C (en) 2013-01-17 2021-10-26 Janssen Pharmaceutica Nv Substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
CA3042877A1 (en) * 2016-11-09 2018-05-17 Bristol-Myers Squibb Company Tricyclic sulfones as ror gamma modulators
US20230137562A1 (en) 2017-06-07 2023-05-04 Adrx, Inc. Tau aggregation inhibitors
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
AU2018318319A1 (en) 2017-08-18 2020-02-20 Adrx, Inc. Tau aggregation peptide inhibitors
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL349781A1 (en) 1999-02-26 2002-09-09 Merck & Co Inc Novel sulfonamide compounds and uses thereof
FR2827590B1 (fr) * 2001-07-18 2003-10-24 Atuser Transbordeur de liquides alimentaires usages
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
WO2003014075A2 (en) * 2001-08-03 2003-02-20 Schering Corporation Novel gamma secretase inhibitors
RU2202370C1 (ru) * 2001-12-26 2003-04-20 Эпштейн Олег Ильич Нейропсихотропное лекарственное средство
GB0222833D0 (en) 2002-10-02 2002-11-06 Syngenta Ltd Chemical process
GB0223039D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
EP1638951B1 (en) * 2003-05-16 2008-02-13 MERCK SHARP & DOHME LTD. Cyclohexyl sulphones as gamma-secretase inhibitors
GB0317491D0 (en) * 2003-07-25 2003-08-27 Novartis Ag Organic compounds
DE102005062098A1 (de) * 2005-12-22 2007-06-28 Merck Patent Gmbh Oxaphenanthren-Derivate
AR059075A1 (es) * 2006-01-20 2008-03-12 Schering Corp Bencesulfonil - cromano , tiocromano tetrahidronaftaleno e inhibidores de gamma secretasa relacionados
TW200813054A (en) 2006-06-02 2008-03-16 Elan Pharm Inc Fused, tricyclic sulfonamide inhibitors of gamma secretase
RU2011123862A (ru) 2008-11-13 2012-12-20 Шеринг Корпорейшн Модуляторы гамма-секретазы

Also Published As

Publication number Publication date
AU2008275735A1 (en) 2009-01-15
AR067445A1 (es) 2009-10-14
CL2008001960A1 (es) 2009-11-27
JP5240871B2 (ja) 2013-07-17
WO2009008980A3 (en) 2009-03-19
CA2691542A1 (en) 2009-01-15
CO6270309A2 (es) 2011-04-20
EP2435416B1 (en) 2016-03-30
RU2010103716A (ru) 2011-08-10
PE20090435A1 (es) 2009-04-18
US20110236400A1 (en) 2011-09-29
TW200908959A (en) 2009-03-01
EP2435416A2 (en) 2012-04-04
CN101754960A (zh) 2010-06-23
WO2009008980A2 (en) 2009-01-15
AU2008275735B2 (en) 2014-03-27
US8664411B2 (en) 2014-03-04
RU2483061C2 (ru) 2013-05-27
ECSP109845A (es) 2010-02-26
AU2008275735A2 (en) 2010-02-11
KR20100044197A (ko) 2010-04-29
JP2010532359A (ja) 2010-10-07
BRPI0814256A2 (pt) 2015-02-03

Similar Documents

Publication Publication Date Title
BRPI0814256A8 (pt) Inibidores de tetrahidropiranocromeno gama secretase
BR0314611A (pt) Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
BRPI0713544B8 (pt) estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia
BRPI0410238A (pt) compostos orgánicos
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
BRPI0507034A (pt) compostos orgánicos
BR112014024479A8 (pt) Formulações farmacêuticas compreendendo antagonistas de c-cr3
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
BR112022000782A2 (pt) Composto, composição farmacêutica, processo para preparar um composto, composto intermediário, e, uso de um composto, ou de um sal farmaceuticamente aceitável ou solvato do mesmo, ou de uma composição farmacêutica
BRPI0411738A (pt) compostos orgánicos
BRPI0713381A2 (pt) composto, composição farmacêutica, e, método para o tratamento de uma doença
CY1112191T1 (el) Παραγωγο πυραζολοπυριμιδινης
BRPI0517455A (pt) compostos orgánicos
BR0308419A (pt) Derivados de azetidina como antagonistas do receptor ccr-3
BRPI0713743B8 (pt) composto, e, composição farmacêutica
BRPI0615691A8 (pt) Método para a preparação de 6-((3s,4r)-4-(4-amino-5-cloro-2-metoxibenzamido)-3-metoxipiperidin-1-il) hexanoato de (r)-quinuclidin-3-ila ou sal do mesmo
BRPI0519208A2 (pt) derivados de pirrolinÍdio como receptores muscarÍnicos m3
ECSP099045A (es) Sal xinafoato de un compuesto de 5-oxazol-2-il-quinolina sustituido
BR112022021865A2 (pt) Derivados de tetrazol como inibidores de trpa1
BR112022009856A2 (pt) Compostos de 1,8-naftiridin-2-ona para o tratamento de doença autoimune
BRPI0513272A (pt) compostos orgánicos
BR112015003281A2 (pt) derivados de diazepinona úteis para o tratamento de síndrome x frágil, doença de parkinson ou por refluxo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.